Logo image of EQ

EQUILLIUM INC (EQ) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:EQ - US29446K1060 - Common Stock

1.1199 USD
-0.03 (-2.62%)
Last: 1/13/2026, 12:32:32 PM
Fundamental Rating

3

Taking everything into account, EQ scores 3 out of 10 in our fundamental rating. EQ was compared to 528 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for EQ as it has an excellent financial health rating, but there are worries on the profitability. EQ does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

EQ had negative earnings in the past year.
In the past year EQ has reported a negative cash flow from operations.
EQ had negative earnings in each of the past 5 years.
In the past 5 years EQ always reported negative operating cash flow.
EQ Yearly Net Income VS EBIT VS OCF VS FCFEQ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of EQ (-70.76%) is worse than 63.07% of its industry peers.
EQ has a Return On Equity (-78.92%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -70.76%
ROE -78.92%
ROIC N/A
ROA(3y)-45.84%
ROA(5y)-43.62%
ROE(3y)-98.95%
ROE(5y)-79.65%
ROIC(3y)N/A
ROIC(5y)N/A
EQ Yearly ROA, ROE, ROICEQ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 -100 -150

1.3 Margins

EQ does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EQ Yearly Profit, Operating, Gross MarginsEQ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

8

2. Health

2.1 Basic Checks

EQ does not have a ROIC to compare to the WACC, probably because it is not profitable.
EQ has more shares outstanding than it did 1 year ago.
The number of shares outstanding for EQ has been increased compared to 5 years ago.
There is no outstanding debt for EQ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EQ Yearly Shares OutstandingEQ Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
EQ Yearly Total Debt VS Total AssetsEQ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 2.02 indicates that EQ is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.02, EQ is doing good in the industry, outperforming 66.67% of the companies in the same industry.
EQ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.02
ROIC/WACCN/A
WACC8.82%
EQ Yearly LT Debt VS Equity VS FCFEQ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 10.85 indicates that EQ has no problem at all paying its short term obligations.
The Current ratio of EQ (10.85) is better than 85.42% of its industry peers.
A Quick Ratio of 10.85 indicates that EQ has no problem at all paying its short term obligations.
EQ has a Quick ratio of 10.85. This is amongst the best in the industry. EQ outperforms 85.42% of its industry peers.
Industry RankSector Rank
Current Ratio 10.85
Quick Ratio 10.85
EQ Yearly Current Assets VS Current LiabilitesEQ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for EQ have decreased strongly by -342.86% in the last year.
The Revenue for EQ has decreased by -90.43% in the past year. This is quite bad
EPS 1Y (TTM)-342.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-90.43%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, EQ will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.60% on average per year.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y-231.39%
EPS Next 2Y-75.15%
EPS Next 3Y0.49%
EPS Next 5Y11.6%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

EQ Yearly Revenue VS EstimatesEQ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 10M 20M 30M 40M
EQ Yearly EPS VS EstimatesEQ Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

EQ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EQ. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EQ Price Earnings VS Forward Price EarningsEQ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EQ Per share dataEQ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-75.15%
EPS Next 3Y0.49%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EQ!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

EQUILLIUM INC

NASDAQ:EQ (1/13/2026, 12:32:32 PM)

1.1199

-0.03 (-2.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-25 2026-03-25/amc
Inst Owners45.87%
Inst Owner Change0%
Ins Owners14.11%
Ins Owner Change-1.38%
Market Cap68.19M
Revenue(TTM)4.39M
Net Income(TTM)-24.42M
Analysts84
Price Target2.55 (127.7%)
Short Float %1.97%
Short Ratio1.46
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.93%
Min EPS beat(2)16.03%
Max EPS beat(2)59.83%
EPS beat(4)4
Avg EPS beat(4)39.05%
Min EPS beat(4)16.03%
Max EPS beat(4)59.83%
EPS beat(8)8
Avg EPS beat(8)58.68%
EPS beat(12)12
Avg EPS beat(12)84.03%
EPS beat(16)13
Avg EPS beat(16)61.88%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)62.96%
EPS NQ rev (3m)63.42%
EPS NY rev (1m)0.67%
EPS NY rev (3m)-3.74%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.53
P/FCF N/A
P/OCF N/A
P/B 2.2
P/tB 2.2
EV/EBITDA N/A
EPS(TTM)-0.62
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0.07
BVpS0.51
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -70.76%
ROE -78.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.84%
ROA(5y)-43.62%
ROE(3y)-98.95%
ROE(5y)-79.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.92%
Cap/Sales 0.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.85
Quick Ratio 10.85
Altman-Z 2.02
F-Score3
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)111.69%
Cap/Depr(5y)164.16%
Cap/Sales(3y)0.71%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-342.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-231.39%
EPS Next 2Y-75.15%
EPS Next 3Y0.49%
EPS Next 5Y11.6%
Revenue 1Y (TTM)-90.43%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-259.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-295.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-295%
OCF growth 3YN/A
OCF growth 5YN/A

EQUILLIUM INC / EQ FAQ

Can you provide the ChartMill fundamental rating for EQUILLIUM INC?

ChartMill assigns a fundamental rating of 3 / 10 to EQ.


Can you provide the valuation status for EQUILLIUM INC?

ChartMill assigns a valuation rating of 0 / 10 to EQUILLIUM INC (EQ). This can be considered as Overvalued.


What is the profitability of EQ stock?

EQUILLIUM INC (EQ) has a profitability rating of 0 / 10.


What is the earnings growth outlook for EQUILLIUM INC?

The Earnings per Share (EPS) of EQUILLIUM INC (EQ) is expected to decline by -231.39% in the next year.